cBAT - CBAT

CBAK Energy Tech (NASDAQ:CBAT) Bolsa

CBAK Energy Tech

CBAK Energy Technology Inc is engaged in the manufacture, commercialization, and distribution of a variety of standard and customized lithium and sodium high-power rechargeable batteries. The batteries are used in light electric vehicles, electric vehicles, energy storage devices, and other high-power applications. The company has two operating segments: CBAK, which derives maximum revenue, and includes the manufacturing, commercialization, and distribution of various standard and customized lithium-ion rechargeable batteries; and the Hitrans segment, which includes the development and manufacturing of NCM precursor and cathode materials. Geographically, the company derives its key revenue from Mainland China, followed by Europe and other regions.

CBAK Energy Technology, Inc. - Common Stock

CBAK Energy Technology Inc

News

Offerings

IMAB

I-Mab Prices 33,333,334 ADS Offering At $1.95/ADS For Gross Proceeds ~$65M

<p>RBC Bearings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBC#NYSE">RBC</a>) sees Q2 sales of $445.000 million-$455.000 million vs $428.198 million analyst estimate.</p>


Guidance

RBC Bearings Sees Q2 Sales $445.000M-$455.000M vs $428.198M Est

<p>RBC Bearings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBC#NYSE">RBC</a>) reported quarterly earnings of $2.84 per share which beat the analyst consensus estimate of $2.75 by 3.35 percent. This is a 11.81 percent increase over earnings of $2.54 per share from the same period last year.  The company reported quarterly sales of $436.000 million which beat the analyst consensus estimate of $432.632 million by 0.78 percent.  This is a 7.31 percent increase over sales of $406.300 million the same period last year.</p>


Earnings

Earnings Beats

RBC Bearings Q1 Adj. EPS $2.84 Beats $2.75 Estimate, Sales $436.000M Beat $432.632M Estimate

Sports Betting

General

GENI

Genius Sports Secures Exclusive Betting Data Rights For Group Of Competitions Within The European Leagues Association

<p>Rosenblatt  analyst Catharine Trebnick   downgrades CyberArk Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYBR#NASDAQ">CYBR</a>) from Buy to Neutral and maintains the price target from $445 to $445.</p>


Downgrades

Price Target

Analyst Ratings

CYBR

Rosenblatt Downgrades CyberArk Software to Neutral, Maintains Price Target to $445

NXGL

NEXGEL Announces $950,000 Registered Direct Offering Of 413,044 Shares At $2.30/Share; Announces A Concurrent Private Placement

<p>6 analysts have shared their evaluations of Builders FirstSource (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLDR#NYSE">BLDR</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $135.83, along with a high estimate of $155.00 and a low estimate of $118.00. This current average represents a 9.75% decrease from the previous average price target of $150.50. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1754049842_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The standing of Builders FirstSource among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Manthey</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$130.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Tyler Batory</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$155.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Jay McCanless</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$145.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Mike Dahl</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$132.00</td>
<td>$132.00</td>
</tr>
<tr>
<td>W. Andrew Carter</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$118.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Ketan Mamtora</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$135.00</td>
<td>$146.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Builders FirstSource. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Builders FirstSource compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Builders FirstSource's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Builders FirstSource's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/BLDR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Builders FirstSource analyst ratings.</strong></a></p>
<h2>About Builders FirstSource</h2>
<p>Builders FirstSource Inc is a manufacturer and supplier of building materials. The company offers structural and related building products such as factory-built roof and floor trusses, wall panels and stairs, vinyl windows, custom millwork and trim, and engineered wood. The products can be designed for each home individually and are installed by Builders FirstSource. The company's construction-related services include professional installation, turn-key framing, and shell construction. Builders FirstSource's customers range from large production builders to small custom homebuilders.</p>
<h3>A Deep Dive into Builders FirstSource's Financials</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Decline in Revenue:</strong> Over the 3M period, Builders FirstSource faced challenges, resulting in a decline of approximately <strong>-6.01%</strong> in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>2.63%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>2.22%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Builders FirstSource's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>0.87%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> Builders FirstSource's debt-to-equity ratio surpasses industry norms, standing at <strong>1.17</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


BLDR

What 6 Analyst Ratings Have To Say About Builders FirstSource

<p>4 analysts have shared their evaluations of iRhythm Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRTC#NASDAQ">IRTC</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $163.5, a high estimate of $180.00, and a low estimate of $147.00. This upward trend is apparent, with the current average reflecting a 14.54% increase from the previous average price target of $142.75.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1754049783_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>A clear picture of iRhythm Technologies's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$180.00</td>
<td>$151.00</td>
</tr>
<tr>
<td>Cecilia Furlong</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$147.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Cecilia Furlong</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$160.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$167.00</td>
<td>$130.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to iRhythm Technologies. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of iRhythm Technologies compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of iRhythm Technologies's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of iRhythm Technologies's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/IRTC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on iRhythm Technologies analyst ratings.</strong></a></p>
<h2>All You Need to Know About iRhythm Technologies</h2>
<p>iRhythm Technologies Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.</p>
<h3>iRhythm Technologies: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> iRhythm Technologies's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of <strong>20.27%</strong>. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> iRhythm Technologies's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>-19.35%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> iRhythm Technologies's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-34.58%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> iRhythm Technologies's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-3.31%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> iRhythm Technologies's debt-to-equity ratio surpasses industry norms, standing at <strong>8.49</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


IRTC

Breaking Down iRhythm Technologies: 4 Analysts Share Their Views

<p>Insperity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSP#NYSE">NSP</a>) lowers FY2025 Adj EPS guidance from $2.23-$3.28 to $1.81-$2.51 vs $2.48 analyst estimate..</p>


Insperity Lowers FY2025 Adj EPS Guidance from $2.23-$3.28 to $1.81-$2.51 vs $2.48 Est

<p>4 analysts have shared their evaluations of Olaplex Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLPX#NASDAQ">OLPX</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $1.73, a high estimate of $2.00, and a low estimate of $1.40. This upward trend is apparent, with the current average reflecting a 4.85% increase from the previous average price target of $1.65.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1754049740_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Olaplex Hldgs by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$2.00</td>
<td>$2.00</td>
</tr>
<tr>
<td>Lauren Lieberman</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$1.50</td>
<td>$1.40</td>
</tr>
<tr>
<td>Lauren Lieberman</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$1.40</td>
<td>$1.20</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$2.00</td>
<td>$2.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Olaplex Hldgs. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Olaplex Hldgs compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Olaplex Hldgs's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Olaplex Hldgs's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/OLPX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Olaplex Hldgs analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>Unveiling the Story Behind Olaplex Hldgs</h2>
<p>Olaplex Holdings Inc is a science-enabled, technology-driven beauty company. It offers science-backed solutions that improve hair health. It identifies the majority of consumers' relevant haircare concerns in collaboration with the community of professional hairstylists and consumers and strives to address them through its proprietary technology and innovation capabilities. It offers products through an omnichannel platform that serves professional, specialty retail, and DTC channels. The company derives its revenue through the sale of its hair care products. The company generates the majority of revenue from Professional sales channels followed by Specialty Retail and then DTC. Geographically the company generates the majority of its revenue from the International market.</p>
<h3>Olaplex Hldgs's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Olaplex Hldgs's financials over 3M reveals challenges. As of 31 March, 2025, the company experienced a decline of approximately <strong>-1.95%</strong> in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Consumer Staples sector.</p>
<p><strong>Net Margin:</strong> Olaplex Hldgs's net margin is impressive, surpassing industry averages. With a net margin of <strong>0.48%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Olaplex Hldgs's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>0.05%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Olaplex Hldgs's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>0.03%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.74</strong>.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


OLPX

Demystifying Olaplex Hldgs: Insights From 4 Analyst Reviews

W.W. Grainger Lowers FY2025 GAAP EPS Guidance from $39.00-$41.50 to $38.50-$40.25 vs $40.52 Est; Raises FY2025 Sales Guidance from $17.600B-$18.100B to $17.900B-$18.200B vs $17.921B Est

<p>5 analysts have shared their evaluations of Five9 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVN#NASDAQ">FIVN</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $34.2, a high estimate of $36.00, and a low estimate of $31.00. A 18.57% drop is evident in the current average compared to the previous average price target of $42.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1754049723_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Five9. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Catharine Trebnick</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$36.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>James Fish</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$31.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Jackson Ader</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Overweight</td>
<td>$35.00</td>
<td>-</td>
</tr>
<tr>
<td>Catharine Trebnick</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$36.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$33.00</td>
<td>$60.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Five9. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Five9 compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Capture valuable insights into Five9's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/FIVN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Five9 analyst ratings.</strong></a></p>
<h2>All You Need to Know About Five9</h2>
<p>Five9 offers cloud-native contact center software enabling digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement, and various modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's modules include digital self-service, agent assist technology, workflow automation, as well as workforce optimization solutions that optimize call center efficiency, and manage interaction quality and agent performance.</p>
<h3>Financial Milestones: Five9's Journey</h3>
<p><strong>Market Capitalization:</strong> Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.</p>
<p><strong>Revenue Growth:</strong> Five9's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of <strong>13.24%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Information Technology sector.</p>
<p><strong>Net Margin:</strong> Five9's net margin excels beyond industry benchmarks, reaching <strong>0.21%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Five9's ROE excels beyond industry benchmarks, reaching <strong>0.09%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Five9's ROA excels beyond industry benchmarks, reaching <strong>0.03%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>1.86</strong>, Five9 adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


FIVN

What 5 Analyst Ratings Have To Say About Five9

<p>Insperity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSP#NYSE">NSP</a>) is looking for Q3 Adj EPS of $0.06-$0.49 vs $0.32 analyst estimate..</p>


Insperity Sees Q3 Adj EPS $0.06-$0.49 vs $0.32 Est

<p>Analysts' ratings for Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) over the last quarter vary from bullish to bearish, as provided by 4 analysts.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $429.5, a high estimate of $455.00, and a low estimate of $400.00. Marking an increase of 3.18%, the current average surpasses the previous average price target of $416.25. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1754049662_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Stryker. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$448.00</td>
<td>$442.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$415.00</td>
<td>$390.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$455.00</td>
<td>$443.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$400.00</td>
<td>$390.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Stryker. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Stryker compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Stryker's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Stryker's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/SYK/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Stryker analyst ratings.</strong></a></p>
<h2>Delving into Stryker's Background</h2>
<p>Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Roughly one fourth of Stryker's total revenue currently comes from outside the United States.</p>
<h3>Financial Milestones: Stryker's Journey</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Stryker's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>11.88%</strong> as of 31 March, 2025, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Stryker's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>11.15%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Stryker's ROE excels beyond industry benchmarks, reaching <strong>3.15%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>1.47%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.8</strong>.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Beyond The Numbers: 4 Analysts Discuss Stryker Stock

<p>Rosenblatt  analyst Steven Frankel   maintains Dolby Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLB#NYSE">DLB</a>) with a Buy and maintains $95 price target.</p>


Rosenblatt Maintains Buy on Dolby Laboratories, Maintains $95 Price Target

<p>Insperity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSP#NYSE">NSP</a>) reported quarterly earnings of $0.26 per share which missed the analyst consensus estimate of $0.43 by 38.97 percent. This is a 69.77 percent decrease over earnings of $0.86 per share from the same period last year.  The company reported quarterly sales of $1.658 billion which missed the analyst consensus estimate of $1.662 billion by 0.24 percent.  This is a 3.30 percent increase over sales of $1.605 billion the same period last year.</p>


Earnings Misses

Insperity Q2 Adj. EPS $0.26 Misses $0.43 Estimate, Sales $1.658B Miss $1.662B Estimate

<p>W.W. Grainger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWW#NYSE">GWW</a>) reported quarterly earnings of $9.97 per share which missed the analyst consensus estimate of $10.04 by 0.65 percent. This is a 2.15 percent increase over earnings of $9.76 per share from the same period last year.  The company reported quarterly sales of $4.554 billion which beat the analyst consensus estimate of $4.522 billion by 0.70 percent.  This is a 5.61 percent increase over sales of $4.312 billion the same period last year.</p>


W.W. Grainger Q2 Adj. EPS $9.97 Misses $10.04 Estimate, Sales $4.554B Beat $4.522B Estimate

<p>Analysts' ratings for Monolithic Power Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPWR#NASDAQ">MPWR</a>) over the last quarter vary from bullish to bearish, as provided by 8 analysts.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Monolithic Power Systems and provided 12-month price targets. The average target is $796.25, accompanied by a high estimate of $940.00 and a low estimate of $695.00. This upward trend is apparent, with the current average reflecting a 7.24% increase from the previous average price target of $742.50.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1754049629_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>The standing of Monolithic Power Systems among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kevin Garrigan</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$800.00</td>
<td>$800.00</td>
</tr>
<tr>
<td>N. Quinn Bolton</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$820.00</td>
<td>$800.00</td>
</tr>
<tr>
<td>Gary Mobley</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$800.00</td>
<td>$760.00</td>
</tr>
<tr>
<td>Joe Quatrochi</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$730.00</td>
<td>$695.00</td>
</tr>
<tr>
<td>Rick Schafer</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$800.00</td>
<td>$700.00</td>
</tr>
<tr>
<td>John Vinh</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$940.00</td>
<td>$820.00</td>
</tr>
<tr>
<td>Joe Quatrochi</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$695.00</td>
<td>$665.00</td>
</tr>
<tr>
<td>Kelsey Chia</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$785.00</td>
<td>$700.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Monolithic Power Systems. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Monolithic Power Systems compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Monolithic Power Systems's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Monolithic Power Systems's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/MPWR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Monolithic Power Systems analyst ratings.</strong></a></p>
<h2>All You Need to Know About Monolithic Power Systems</h2>
<p>Monolithic Power Systems is an analog and mixed-signal chipmaker, specializing in power management solutions. The firm's mission is to reduce total energy consumption in end systems, and it serves the computing, automotive, industrial, communications, and consumer end markets. MPS uses a fabless manufacturing model, partnering with third-party chip foundries to host its proprietary BCD process technology.</p>
<h3>Financial Insights: Monolithic Power Systems</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Over the 3M period, Monolithic Power Systems showcased positive performance, achieving a revenue growth rate of <strong>39.24%</strong> as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Information Technology sector.</p>
<p><strong>Net Margin:</strong> Monolithic Power Systems's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>20.98%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>4.17%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Monolithic Power Systems's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>3.6%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.0</strong>.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


MPWR

Analyst Expectations For Monolithic Power Systems's Future

<p><figure class="wp-block-image aligncenter size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/08/01060853/Anime-Coma-1024x576.jpg" alt="" class="wp-image-16786" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/08/01060853/Anime-Coma-1024x576.jpg 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/08/01060853/Anime-Coma-300x169.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/08/01060853/Anime-Coma-768x432.jpg 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/08/01060853/Anime-Coma.jpg 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure></p>
<p><strong><em>Image source: Author</em></strong></p>
<h2 class="wp-block-heading">What TransMedics Just Taught Us About Trusting The Algorithm</h2>
<h3 class="wp-block-heading">1. A thriller that still haunts ICUs</h3>
<p>Back in Robin Cook's 1977 novel&nbsp;<em>Coma</em>—and Michael Crichton's 1978 film adaptation—healthy patients are deliberately pushed into irreversible comas so their organs can be harvested and sold on the black market.</p>
<p>Fast-forward to July 20, 2025:&nbsp;<em>The New York Times</em>&nbsp;ran a&nbsp;<a href="https://archive.ph/kyxDj">chilling investigation</a>&nbsp;headlined&nbsp;<strong>"A Push for More Organ Transplants Is Putting Donors at Risk."</strong>&nbsp;It documented cases where organs were nearly removed from patients who were still showing signs of life—prompting UNOS, the nonprofit that oversees U.S. transplantation logistics, to issue&nbsp;<a href="https://unos.org/media-resources/releases/unos-ceo-maureen-mcbride-responds-to-july-20-new-york-times-article/">an unusually sharp public response</a>&nbsp;the very next day.</p>
<p>One of the companies mentioned in that Times article was&nbsp;<strong>TransMedics Group, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>), the market leader in "organ-in-a-box" perfusion technology.</p>
<hr class="wp-block-separator has-alpha-channel-opacity" />
<h3 class="wp-block-heading">2. Could negative headlines swamp the algo signal?</h3>
<p>Four days later—<strong>on 7/24/25—our weekly algorithmic screen flagged TMDX as one of its Top Ten names</strong>.</p>
<p>Ordinarily, that would have been all the conviction I needed. Since December of 2022, our weekly top ten names delivered an <strong>average six-month return of ≈ 16.25 %</strong>, ahead of SPY's <strong>≈ 9.21 %</strong> over the same spans.</p>
<p>But the grisly details in the Times piece triggered a human hesitation:&nbsp;<em>Could negative headlines swamp the algo signal?</em>&nbsp;I passed on the trade.</p>
<hr class="wp-block-separator has-alpha-channel-opacity" />
<h3 class="wp-block-heading">3. What happened next</h3>
<p>After Tuesday's close (7/30), TransMedics&nbsp;<a href="https://www.prnewswire.com/news-releases/transmedics-reports-second-quarter-2025-financial-results-302517787.html?utm_source=chatgpt.com">reported</a>&nbsp;<strong>Q2 GAAP EPS of $0.92—beating consensus by $0.47—and revenue of $157.4 million—beating by $9.65 million</strong>.</p>
<ul class="wp-block-list">
<li><strong>Price reaction:</strong>&nbsp;From the 7/24 close of&nbsp;<strong>$106.79</strong>&nbsp;to the 7/31 close of&nbsp;<strong>$118.97</strong>, TMDX rallied&nbsp;<strong>+11.4 %</strong>&nbsp;in five trading days.</li>
<li><strong>Missed alpha:</strong>&nbsp;That single decision left nearly a fifth of the Top-Ten cohort's week-one outperformance on the table.&nbsp;<strong>And that double-digit gain in the underlying stock would have translated to a triple-digit gain in an options trade</strong>&nbsp;over the same time frame.</li>
<li><strong>The NY Times</strong> flips on organ donations. On 7/31, they published an op-ed saying medicine should expand the definition of death. That way, companies like TransMedics would be able to harvest more organs from patients. </li>
</ul>
<p><figure class="wp-block-image size-full"><a href="https://x.com/sjauhar/status/1950863258170134922"><img loading="lazy" decoding="async" width="691" height="865" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/08/01111929/X-post.jpg" alt="" class="wp-image-16805" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/08/01111929/X-post.jpg 691w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/08/01111929/X-post-240x300.jpg 240w" sizes="(max-width: 691px) 100vw, 691px" /></a></figure></p>
<hr class="wp-block-separator has-alpha-channel-opacity" />
<h3 class="wp-block-heading">4. The lesson</h3>
<p>Subjective overlays—especially emotionally charged ones—can feel safer, but they often dilute systematic edge. Our algorithm cared only about forward-looking return asymmetry; it didn't flinch at sensational headlines, and it was right.</p>
<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow"><p><strong>Key takeaway:</strong>&nbsp;<em>If you've hired a disciplined quantitative bouncer to pick your guests, don't second-guess the door list because the guy from the tabloids is shouting outside.</em></p>
<p><strong><em>Benzinga Disclaimer: This article is from an unpaid external contributor. It does not represent Benzinga&#8217;s reporting and has not been edited for content or accuracy.</em></strong></p>
<p>&#x2A;&#x2A;&#x2A;</p>
</blockquote>
<h3 class="wp-block-heading">Where to get the signals</h3>
<ul class="wp-block-list">
<li><strong>Weekly Top Ten</strong>&nbsp;posts drop every Thursday on the Portfolio Armor Substack. You can subscribe to it&nbsp;<a href="https://blog.portfolioarmor.com/">here</a>.&nbsp;</li>
</ul>
<p><figure class="wp-block-image aligncenter size-full"><a href="https://blog.portfolioarmor.com/"><img loading="lazy" decoding="async" width="581" height="372" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/08/01061052/Widget.jpg" alt="" class="wp-image-16787" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/08/01061052/Widget.jpg 581w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/08/01061052/Widget-300x192.jpg 300w" sizes="(max-width: 581px) 100vw, 581px" /></a></figure></p>


Equities

Options

Opinion

Trading Ideas

TMDX

What TransMedics Just Taught Me About Trusting The Algorithm

FOXO

FOXO's Big South Fork Medical Center Joins Covenant Health Network To Offer Swing Bed Services, Advancing Post-Acute Care Access In East Tennessee

Press Releases

CBAK Energy Captures 14.6% Share of 32140 Cylindrical Cell Market in Q1 2025

CBAK Energy to Participate in Shenzhen International Battery Technology Conference & Expo on Tuesday, May 15, 2025

CBAK Energy to Report First Quarter 2025 Unaudited Financial Results on Monday, May 19, 2025

CBAK Energy Reports First Quater 2025 Unaudited Financial Results

CBAK Energy to Participate in The Battery Show Europe on June 3, 2025

CBAK Energy Launches Share Buyback Program Authorizing Repurchase of Up to $20 Million in Common Stock Over the Next 12 Months

Contracts

CBAK Energy Secures $3 Million Follow-up Order from Livguard, Strengthening Strategic Partnership in India

CBAK Energy Announces $11.6 Million Order from Africa's largest EV player

CBAK Energy Engages FAW, one of China's largest EV makers, in Strategic Talks on New EV Battery Model 46950

CBAK Energy Forms Strategic Partnership with Anker Innovations to Establish Battery Cell Manufacturing Facility in Malaysia, with Potential Orders Valued at Up to US$357 Million

CBAT

ADS-TEC Energy

Asia Pacific Wire & Cable Corporation Limited - Common shares, Par value .01 per share

Comments

CBAK Energy Tech

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL